Cyclacel Pharmaceuticals, Inc. (CYCC) financial statements (2021 and earlier)

Company profile

Business Address 200 CONNELL DRIVE
BERKELEY HEIGHTS, NJ 07922
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments33121824172043
Cash and cash equivalents33121824172024
Short-term investments      18
Receivables  00 00
Prepaid expense 110111
Disposal group, including discontinued operation     00
Deposits current assets  00000
Other current assets00000 0
Other undisclosed current assets211123(15)
Total current assets:35142026202529
Noncurrent Assets
Operating lease, right-of-use asset11
Property, plant and equipment0000000
Total noncurrent assets:1100000
TOTAL ASSETS:37152026202529
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2244567
Accounts payable1132223
Accrued liabilities2223345
Disposal group, including discontinued operation     00
Total current liabilities:2244567
Noncurrent Liabilities
Long-term debt and lease obligation11     
Operating lease, liability11
Liabilities, other than long-term debt   0000
Other liabilities   0000
Other undisclosed noncurrent liabilities  0    
Total noncurrent liabilities:1100000
Total liabilities:4454568
Stockholders' equity
Stockholders' equity attributable to parent33121522141922
Common stock0000000
Additional paid in capital400370366365350343331
Accumulated other comprehensive loss(1)(1)(1)(1)(1)(1)(0)
Accumulated deficit(366)(358)(350)(343)(335)(323)(309)
Total stockholders' equity:33121522141922
TOTAL LIABILITIES AND EQUITY:37152026202529

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues  0 122
Revenue, net 122
Cost of revenue (0)  (0)  
Gross profit: (0)0 122
Operating expenses(11)(10)(10)(9)(15)(18)(24)
Operating loss:(11)(10)(10)(9)(14)(16)(22)
Nonoperating income (expense)11110(0)(0)
Investment income, nonoperating0000000
Foreign currency transaction gain (loss), before tax00(0)(0)0(0)(0)
Other nonoperating income1011000
Loss from continuing operations before income taxes:(10)(9)(9)(8)(14)(16)(23)
Income tax benefit1111223
Loss from continuing operations:(8)(8)(7)(7)(12)(14)(19)
Income from discontinued operations      0
Net loss attributable to parent:(8)(8)(7)(7)(12)(14)(19)
Preferred stock dividends and other adjustments(4)(0)(0)(0)(0)  
Other undisclosed net loss available to common stockholders, basic     (0)(0)
Net loss available to common stockholders, basic:(12)(8)(7)(8)(12)(15)(20)
Other undisclosed net loss available to common stockholders, diluted   (7)   
Net loss available to common stockholders, diluted:(12)(8)(7)(15)(12)(15)(20)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(8)(8)(7)(7)(12)(14)(19)
Comprehensive loss:(8)(8)(7)(7)(12)(14)(19)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent0(0)0(0)   
Comprehensive loss, net of tax, attributable to parent:(8)(8)(7)(8)(12)(14)(19)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: